Drug Type Small molecule drug |
Synonyms 10-[2-(1-methyl-2-piperidyl)ethyl]-2-methylsulfanyl-phenothiazine, 2-Methylmercapto-10-(2-(N-methyl-2-piperidyl)ethyl)phenothiazine, 3-Methylmercapto-N-(2'-(N-methyl-2-piperidyl)ethyl)phenothiazine + [7] |
Mechanism 5-HT2A receptor antagonists(Serotonin 2a (5-HT2a) receptor antagonists), D1 receptor antagonists(Dopamine D1 receptor antagonists), D2 receptor antagonists(Dopamine D2 receptor antagonists) + [3] |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date US (18 Oct 1978), |
Regulation- |
Molecular FormulaC21H26N2S2 |
InChIKeyKLBQZWRITKRQQV-UHFFFAOYSA-N |
CAS Registry50-52-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00373 | Thioridazine |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hepatocellular Carcinoma | Phase 3 | CN | 29 Aug 2022 | |
Diffuse Large B-Cell Lymphoma | Preclinical | DE | 01 Dec 2012 |
Phase 1 | 13 | qndmomigtl(oteipbcduf) = kdftqwftfi svvpelduos (kzwidqirwm ) View more | - | 14 Aug 2018 |